Local release of dexamethasone from polymer millirods effectively prevents fibrosis after radiofrequency ablation

Elvin Blanco, Brent D. Weinberg, Nicholas T. Stowe, James M. Anderson, Jinming Gao

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Recent studies show that after radiofrequency (RF) ablation, fibrosis occurs at the ablation boundary, hindering anticancer drug transport from a locally implanted polymer depot to the ablation margin, where tumors recur. The purpose of this study is to investigate strategies that can effectively deliver dexamethasone (DEX), an anti-inflammatory agent, to prevent fibrosis. Polymer millirods consisting of poly(D,L-lactide-co-glycolide) (PLGA) were loaded with either DEX complexed with hydroxypropyl β-cyclodextrin (HPβ-CD), or an NaCl and DEX mixture. In vitro release studies show that DEX complexed with HPβ-CD released 95% of the drug after 4 days, compared to 14% from millirods containing NaCl and DEX. Rat livers underwent RF ablation and received either DEX-HPβ-CD-loaded millirods, PLGA millirods with an intraperitoneal (i.p.) DEX injection, or control PLGA millirods alone. After 8 days in vivo, heightened inflammation and the appearance of a well-defined fibrous capsule can be observed in both the control experiments and those receiving a DEX injection (0.29 ± 0.08 and 0.26 ± 0.07 mm in thickness, respectively), with minimal inflammation and fibrosis present in livers receiving DEX millirods (0.04 ± 0.01 mm). Results from this study show that local release of DEX prevents fibrosis more effectively than a systemic i.p. injection.

Original languageEnglish (US)
Pages (from-to)174-182
Number of pages9
JournalJournal of Biomedical Materials Research - Part A
Volume76
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Ablation
Dexamethasone
Cyclodextrins
Polymers
Liver
Rats
Tumors
Pharmaceutical Preparations
Experiments
Capsules
Anti-Inflammatory Agents
polylactic acid-polyglycolic acid copolymer

Keywords

  • Dexamethasone
  • Fibrous capsule formation
  • Inflammation
  • Polymer implant
  • Radiofrequency ablation

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials

Cite this

Local release of dexamethasone from polymer millirods effectively prevents fibrosis after radiofrequency ablation. / Blanco, Elvin; Weinberg, Brent D.; Stowe, Nicholas T.; Anderson, James M.; Gao, Jinming.

In: Journal of Biomedical Materials Research - Part A, Vol. 76, No. 1, 01.2006, p. 174-182.

Research output: Contribution to journalArticle

Blanco, Elvin ; Weinberg, Brent D. ; Stowe, Nicholas T. ; Anderson, James M. ; Gao, Jinming. / Local release of dexamethasone from polymer millirods effectively prevents fibrosis after radiofrequency ablation. In: Journal of Biomedical Materials Research - Part A. 2006 ; Vol. 76, No. 1. pp. 174-182.
@article{32d0502249304ccb9c1a17b71fe6e615,
title = "Local release of dexamethasone from polymer millirods effectively prevents fibrosis after radiofrequency ablation",
abstract = "Recent studies show that after radiofrequency (RF) ablation, fibrosis occurs at the ablation boundary, hindering anticancer drug transport from a locally implanted polymer depot to the ablation margin, where tumors recur. The purpose of this study is to investigate strategies that can effectively deliver dexamethasone (DEX), an anti-inflammatory agent, to prevent fibrosis. Polymer millirods consisting of poly(D,L-lactide-co-glycolide) (PLGA) were loaded with either DEX complexed with hydroxypropyl β-cyclodextrin (HPβ-CD), or an NaCl and DEX mixture. In vitro release studies show that DEX complexed with HPβ-CD released 95{\%} of the drug after 4 days, compared to 14{\%} from millirods containing NaCl and DEX. Rat livers underwent RF ablation and received either DEX-HPβ-CD-loaded millirods, PLGA millirods with an intraperitoneal (i.p.) DEX injection, or control PLGA millirods alone. After 8 days in vivo, heightened inflammation and the appearance of a well-defined fibrous capsule can be observed in both the control experiments and those receiving a DEX injection (0.29 ± 0.08 and 0.26 ± 0.07 mm in thickness, respectively), with minimal inflammation and fibrosis present in livers receiving DEX millirods (0.04 ± 0.01 mm). Results from this study show that local release of DEX prevents fibrosis more effectively than a systemic i.p. injection.",
keywords = "Dexamethasone, Fibrous capsule formation, Inflammation, Polymer implant, Radiofrequency ablation",
author = "Elvin Blanco and Weinberg, {Brent D.} and Stowe, {Nicholas T.} and Anderson, {James M.} and Jinming Gao",
year = "2006",
month = "1",
doi = "10.1002/jbm.a.30516",
language = "English (US)",
volume = "76",
pages = "174--182",
journal = "Journal of Biomedical Materials Research - Part A",
issn = "0021-9304",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Local release of dexamethasone from polymer millirods effectively prevents fibrosis after radiofrequency ablation

AU - Blanco, Elvin

AU - Weinberg, Brent D.

AU - Stowe, Nicholas T.

AU - Anderson, James M.

AU - Gao, Jinming

PY - 2006/1

Y1 - 2006/1

N2 - Recent studies show that after radiofrequency (RF) ablation, fibrosis occurs at the ablation boundary, hindering anticancer drug transport from a locally implanted polymer depot to the ablation margin, where tumors recur. The purpose of this study is to investigate strategies that can effectively deliver dexamethasone (DEX), an anti-inflammatory agent, to prevent fibrosis. Polymer millirods consisting of poly(D,L-lactide-co-glycolide) (PLGA) were loaded with either DEX complexed with hydroxypropyl β-cyclodextrin (HPβ-CD), or an NaCl and DEX mixture. In vitro release studies show that DEX complexed with HPβ-CD released 95% of the drug after 4 days, compared to 14% from millirods containing NaCl and DEX. Rat livers underwent RF ablation and received either DEX-HPβ-CD-loaded millirods, PLGA millirods with an intraperitoneal (i.p.) DEX injection, or control PLGA millirods alone. After 8 days in vivo, heightened inflammation and the appearance of a well-defined fibrous capsule can be observed in both the control experiments and those receiving a DEX injection (0.29 ± 0.08 and 0.26 ± 0.07 mm in thickness, respectively), with minimal inflammation and fibrosis present in livers receiving DEX millirods (0.04 ± 0.01 mm). Results from this study show that local release of DEX prevents fibrosis more effectively than a systemic i.p. injection.

AB - Recent studies show that after radiofrequency (RF) ablation, fibrosis occurs at the ablation boundary, hindering anticancer drug transport from a locally implanted polymer depot to the ablation margin, where tumors recur. The purpose of this study is to investigate strategies that can effectively deliver dexamethasone (DEX), an anti-inflammatory agent, to prevent fibrosis. Polymer millirods consisting of poly(D,L-lactide-co-glycolide) (PLGA) were loaded with either DEX complexed with hydroxypropyl β-cyclodextrin (HPβ-CD), or an NaCl and DEX mixture. In vitro release studies show that DEX complexed with HPβ-CD released 95% of the drug after 4 days, compared to 14% from millirods containing NaCl and DEX. Rat livers underwent RF ablation and received either DEX-HPβ-CD-loaded millirods, PLGA millirods with an intraperitoneal (i.p.) DEX injection, or control PLGA millirods alone. After 8 days in vivo, heightened inflammation and the appearance of a well-defined fibrous capsule can be observed in both the control experiments and those receiving a DEX injection (0.29 ± 0.08 and 0.26 ± 0.07 mm in thickness, respectively), with minimal inflammation and fibrosis present in livers receiving DEX millirods (0.04 ± 0.01 mm). Results from this study show that local release of DEX prevents fibrosis more effectively than a systemic i.p. injection.

KW - Dexamethasone

KW - Fibrous capsule formation

KW - Inflammation

KW - Polymer implant

KW - Radiofrequency ablation

UR - http://www.scopus.com/inward/record.url?scp=30444459009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444459009&partnerID=8YFLogxK

U2 - 10.1002/jbm.a.30516

DO - 10.1002/jbm.a.30516

M3 - Article

VL - 76

SP - 174

EP - 182

JO - Journal of Biomedical Materials Research - Part A

JF - Journal of Biomedical Materials Research - Part A

SN - 0021-9304

IS - 1

ER -